Trials / Completed
CompletedNCT03603379
Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
A Pharmacokinetic Phase 1 Study of Anti-epidermal Growth Factor Receptor (EGFR) -Immunoliposomes Loaded With Doxorubicin in Patients With Relapsed or Refractory High-grade Gliomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anti-EGFR-immunoliposomes loaded with doxorubicin (C225-ILs-dox) are given intravenously in patients with relapsed or refractory high-grade gliomas. The pharmacokinetics of C225-ILs-dox in peripheral blood (PB), cerebro-spinal fluid (CSF) and resected tumour tissue will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C225-ILs-dox | C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied. |
Timeline
- Start date
- 2018-11-16
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
- First posted
- 2018-07-27
- Last updated
- 2020-12-08
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03603379. Inclusion in this directory is not an endorsement.